Evidence map›Paper›PMID 38178861›Full record

ArticleFrontiers in pharmacology2023

The categorizations of vasculogenic mimicry in clear cell renal cell carcinoma unveil inherent connections with clinical and immune features.

Bo Geng, Weiyang Liu, Jinpeng Wang, Wei Zhang, Zhuolun Li, Nan Zhang, Wenbin Hou, Enyang Zhao, Xuedong Li, Bosen You

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.0field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Bo Geng *Department of Urology, The Second Affiliated Hospital of Harbin Medical University, Harbin, China.
Weiyang Liu *Department of Urology, The Second Affiliated Hospital of Harbin Medical University, Harbin, China.
Jinpeng Wang *Department of Urology, The Second Affiliated Hospital of Harbin Medical University, Harbin, China.
Wei ZhangDepartment of Urology, The Second Affiliated Hospital of Harbin Medical University, Harbin, China.
Zhuolun LiDepartment of Urology, The Second Affiliated Hospital of Harbin Medical University, Harbin, China.
Nan ZhangDepartment of Urology, The Second Affiliated Hospital of Harbin Medical University, Harbin, China.
Wenbin HouDepartment of Urology, The Second Affiliated Hospital of Harbin Medical University, Harbin, China.
Enyang ZhaoDepartment of Urology, The Second Affiliated Hospital of Harbin Medical University, Harbin, China.
Xuedong LiDepartment of Urology, The Second Affiliated Hospital of Harbin Medical University, Harbin, China.
Bosen YouDepartment of Urology, The Second Affiliated Hospital of Harbin Medical University, Harbin, China.
Harbin Medical University · CNSecond Affiliated Hospital of Harbin Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

ccRCCdrug susceptibilitymolecular subtypestumor immune microenvironmentvasculogenic mimicry

Identifiers

PMID38178861
PMCPMC10765515
OpenAlexW4390010254

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.